Jesper Kjerulff

Project lead and COO

Role in PharmNovo: Global project lead.

Born: 1965

Education: MSc chemical engineering and PhD biotechology from Technical University of Denmark, BCom from Copenhagen Business School.

Other current appointments: None.

Work experience: Jesper is a very experienced pharma project leader with global experience across EU, US, China, Japan, and rest of world from early- as well as late-stage drug development projects and with significant experience from interactions with regulatory authorities such as EMA, FDA, PMDA, and CFDA.

For almost two decades, Jesper headed numerous global projects and large, global, cross-functional project teams at Lundbeck across the entire value chain and across small molecules and biologics. He was amongst others global project lead on successful development of Brintellix®/Trintellix® from pre-clinical development over phase I, II, and III clinical development and to registration and launch. Trintellix®/Brintellix® is today a globally launched blockbuster.

Holdings: None.

Member of:

Operational team

Latest news

View all

July 17, 2024

17.5m EUR blended funding from EIC

PharmNovo is very pleased to announce that we have been awarded a 2.5m EUR grant and an opportunity for up to 15m EUR equity investment from the European Innovation Council (EIC) for innovative pain treatment. The equity part being contingent on investments of equal amounts from co-investors.

PharmNovo presenting at the Global Forum

June 5, 2024

PharmNovo presenting at the Global Forum

On May 29–30, BioStock hosted the Global Forum. The event is the first of its kind, aimed at bringing together growth stage Nordic life science companies looking to expand into new markets and experts armed with a profound knowledge of how business is done across the globe.

March 21, 2024

Positive final Phase I results

The final results from the Phase I clinical for our neuropathic pain drug candidate PN6047, demonstrates safety and tolerability and a lack of the adverse effects commonly associated with conventional opioids. The findings from the Phase I trial show that PN6047 is safe and well-tolerated at the doses tested, with no serious adverse events reported.

Meet Bengt von Mentzer, founder and Chief scientific advisor

March 10, 2024

Meet Bengt von Mentzer, founder and Chief scientific advisor

Bengt von Mentzer founded PharmNovo 16 years ago, and today, his visionary approach and scientific process still drive the development of the groundbreaking compound PN6047. At the intersection of innovation and scientific leadership, Bengt von Mentzer is paving the way for how to reshape the landscape of chronic pain treatment.